| Literature DB >> 16250914 |
Manish S Kothari1, Vasilis Kosmoliaptsis2, John Meyrick-Thomas3.
Abstract
BACKGROUND: Gastro Intestinal Stromal Tumors (GISTs) are rare stromal neoplasms that represent the most common mesenchymal tumor of the G.I. tract, accounting for 5% of all sarcomas. Originating from interstitial cells of Cajal, which are regulators of gut peristalsis, they are preferentially located in the stomach and the small intestine and clinical presentation is variable, ranging from vague complaints to major G.I. bleeding. Surgical resection is the mainstay of treatment for patients with resectable GIST and 5-year survival ranges from 21% to 88% in different series depending on risk grading and completeness of surgical resection. Imatinib mesylate, a tyrosine kinase inhibitor, provides an encouraging option for treating high risk GISTs. CASEEntities:
Year: 2005 PMID: 16250914 PMCID: PMC1282588 DOI: 10.1186/1477-7800-2-24
Source DB: PubMed Journal: Int Semin Surg Oncol ISSN: 1477-7800
Figure 1Histopathological appearance of the tumour under low and higher magnification respectively. The tumour consists of densely crowded spindle and polygonal cells with moderate nuclear pleomorphism. It has involved all the layers of the small bowel wall from mucosa outwards to the serosa.
Figure 2Histopathological appearance of the tumour under low and higher magnification respectively. The tumour consists of densely crowded spindle and polygonal cells with moderate nuclear pleomorphism. It has involved all the layers of the small bowel wall from mucosa outwards to the serosa.
Figure 3The tumour stained strongly for CD117 at immunostaining.